3/18
02:34 pm
ions
National Triglyceride Alliance Celebrates One Year of Impact and Recognizes National Triglycerides Day [Yahoo! Finance]
Low
Report
National Triglyceride Alliance Celebrates One Year of Impact and Recognizes National Triglycerides Day [Yahoo! Finance]
3/18
10:32 am
ions
Why Ionis Pharmaceuticals' (IONS) 2026 Catalyst Pipeline Supported Leerink's Higher Target [Yahoo! Finance]
Low
Report
Why Ionis Pharmaceuticals' (IONS) 2026 Catalyst Pipeline Supported Leerink's Higher Target [Yahoo! Finance]
3/9
06:11 pm
ions
Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/9
07:00 am
ions
Ionis announces changes to Board of Directors
Low
Report
Ionis announces changes to Board of Directors
3/3
11:24 am
ions
Ionis Pharmaceuticals (IONS) had its price target raised by Leerink Partners from $102.00 to $104.00. They now have an "outperform" rating on the stock.
Low
Report
Ionis Pharmaceuticals (IONS) had its price target raised by Leerink Partners from $102.00 to $104.00. They now have an "outperform" rating on the stock.
2/28
07:02 pm
ions
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) [Yahoo! Finance]
Low
Report
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) [Yahoo! Finance]
2/28
07:02 pm
ions
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story [Yahoo! Finance]
Low
Report
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story [Yahoo! Finance]
2/28
07:51 am
ions
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance [Yahoo! Finance]
2/27
12:32 pm
ions
Ionis Pharmaceuticals (IONS) had its price target raised by Piper Sandler from $87.00 to $100.00. They now have an "overweight" rating on the stock.
Low
Report
Ionis Pharmaceuticals (IONS) had its price target raised by Piper Sandler from $87.00 to $100.00. They now have an "overweight" rating on the stock.
2/27
07:00 am
ions
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
Low
Report
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
2/27
03:58 am
ions
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/27
12:00 am
ions
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 [Yahoo! Finance]
Low
Report
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 [Yahoo! Finance]
2/26
09:55 am
ions
Ionis Pharmaceuticals (IONS) had its price target raised by Stifel Nicolaus from $73.00 to $77.00. They now have a "hold" rating on the stock.
Low
Report
Ionis Pharmaceuticals (IONS) had its price target raised by Stifel Nicolaus from $73.00 to $77.00. They now have a "hold" rating on the stock.
2/26
07:00 am
ions
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
Low
Report
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
2/25
07:05 pm
ions
Ionis Pharmaceuticals (IONS) was given a new $95.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.
Low
Report
Ionis Pharmaceuticals (IONS) was given a new $95.00 price target by Morgan Stanley. They now have an "overweight" rating on the stock.
2/25
04:27 pm
ions
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
2/25
03:58 pm
ions
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.
Low
Report
Ionis Pharmaceuticals (IONS) had its "buy" rating reaffirmed by Needham & Company LLC.
2/25
03:58 pm
ions
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
Ionis Pharmaceuticals (IONS) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
2/25
02:51 pm
ions
Ionis Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
07:24 am
ions
Ionis Pharmaceuticals: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals: Q4 Earnings Snapshot [Yahoo! Finance]
2/25
07:17 am
ions
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs [Yahoo! Finance]
Low
Report
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs [Yahoo! Finance]
2/25
07:00 am
ions
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
Medium
Report
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
2/20
09:21 pm
ions
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS [Yahoo! Finance]
Low
Report
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS [Yahoo! Finance]
2/19
07:05 am
ions
Ionis to present at upcoming investor conferences
Low
Report
Ionis to present at upcoming investor conferences
2/17
02:58 pm
ions
Ionis updates time for fourth quarter and full year 2025 financial results webcast
Low
Report
Ionis updates time for fourth quarter and full year 2025 financial results webcast